Literature DB >> 23865003

The reasonable timing of the adjuvant radiotherapy in the treatment of uterine carcinosarcoma according to the surgical intent: suggestion based on progression patterns.

Jeong Il Yu1, Doo Ho Choi, Seung Jae Huh, Won Park, Dongryul Oh, Duk Soo Bae.   

Abstract

PURPOSE: We designed this study to identify and suggest the reasonable timing of adjuvant radiotherapy in the treatment of uterine carcinosarcoma according to the surgical intent and patterns of progression.
MATERIALS AND METHODS: We retrospectively analyzed a total of 50 carcinosarcoma patients diagnosed between 1995 and 2010. Among these 50 patients, 32 underwent curative surgery and 13 underwent maximal tumor debulking surgery. The remaining five patients underwent biopsy only. Twenty-six patients received chemotherapy, and 15 patients received adjuvant radiotherapy.
RESULTS: The median follow-up period was 17.3 months. Curative resection (p < 0.001) and stage (p < 0.001) were statistically significant factors affecting survival. During follow-up, 30 patients showed progression. Among these, eight patients (16.0%) had loco-regional progression only. The patients who had received adjuvant radiotherapy did not show loco-regional progression, and radiotherapy was a significant negative risk factor for loco-regional progression (p = 0.01). The time to loco-regional progression was much earlier for non-curative than curative resection (range, 0.7 to 7.6 months vs. 7.5 to 39.0 months).
CONCLUSION: Adjuvant radiotherapy in the treatment of carcinosarcoma might be related to a low loco-regional progression rate. Radiotherapy should be considered in non-curatively resected patients as soon as possible.

Entities:  

Keywords:  Carcinosarcoma; Loco-regional progression; Pattern; Radiotherapy; Surgery

Year:  2013        PMID: 23865003      PMCID: PMC3712176          DOI: 10.3857/roj.2013.31.2.72

Source DB:  PubMed          Journal:  Radiat Oncol J        ISSN: 2234-1900


  18 in total

1.  The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma.

Authors:  Edward J Tanner; Mario M Leitao; Karuna Garg; Dennis S Chi; Yukio Sonoda; Ginger J Gardner; Richard R Barakat; Elizabeth L Jewell
Journal:  Gynecol Oncol       Date:  2011-09-25       Impact factor: 5.482

2.  FIGO staging for carcinosarcoma: can the revised staging system predict overall survival?

Authors:  Tana S Pradhan; Erin E Stevens; Michael Ablavsky; Ghadir Salame; Yi-Chun Lee; Ovadia Abulafia
Journal:  Gynecol Oncol       Date:  2011-09-01       Impact factor: 5.482

3.  Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus.

Authors:  B Robinson-Bennett; R Z Belch; A C Han
Journal:  Int J Gynecol Cancer       Date:  2006 May-Jun       Impact factor: 3.437

4.  The impact of adjuvant radiotherapy on carcinosarcoma of the uterus.

Authors:  K Gerszten; C Faul; S Kounelis; Q Huang; J Kelley; M W Jones
Journal:  Gynecol Oncol       Date:  1998-01       Impact factor: 5.482

5.  Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases.

Authors:  S G Silverberg; F J Major; J A Blessing; B Fetter; F B Askin; S Y Liao; A Miller
Journal:  Int J Gynecol Pathol       Date:  1990       Impact factor: 2.762

6.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Authors:  Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

Review 7.  Adjuvant chemotherapy in early stage uterine sarcomas: an open question.

Authors:  A Gadducci; A Romanini
Journal:  Eur J Gynaecol Oncol       Date:  2001       Impact factor: 0.196

8.  Primary malignant mixed mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI.

Authors:  Sze Yiun Teo; Kemi T Babagbemi; Hope E Peters; Koenraad J Mortele
Journal:  AJR Am J Roentgenol       Date:  2008-07       Impact factor: 3.959

9.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

10.  Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992.

Authors:  S D Tinkler; V J Cowie
Journal:  Br J Radiol       Date:  1993-11       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.